David Ridley
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| David Ridley | |
|---|---|
| Born | |
| 🎓 Alma mater | Duke University (PhD) University of Missouri-Columbia (BS) |
| 💼 Occupation | |
| Known for | priority review voucher, vector expedited review voucher, health economics |
| 🌐 Website | Personal webpage |
David Ridley is a health economist and the Faculty Director for the Center for Health Sector Management at Duke University's Fuqua School of Business.[1] His most influential research focuses on the economics of innovative medical products, particularly the development, manufacturing, and pricing of pharmaceuticals.[2]
Career[edit]
Ridley's research has had a significant effect on public policy. He was the lead author of two articles that became law in the United States.[3]
In 2006, Ridley with Jeffrey Moe and Henry Grabowski, proposed the Food and Drug Administration's priority review voucher program.[4] The voucher program became law in the Food and Drug Administration Amendments Act (FDAAA) of 2007.[5] Ridley was the subject of a profile in the Wall Street Journal, "Medical Miracles From FDA Inefficiency", which explored his career, research, and the significant impacts of the voucher program on drug development for rare diseases.[6]
In 2015, Ridley, Jeffrey Moe, and Nick Hamon proposed the Environmental Protection Agency's vector expedited review voucher (VERV) program.[7] It became law seven years later in the Pesticide Registration and Improvement Act of 2022.[8]
Since 2013, Ridley has served as the Faculty Director for the Center for Health Sector Management,[9] one of the largest health sector programs at a leading business school.[10]
Ridley also teaches and mentors students. He was named a favorite business school MBA professor in Poets and Quants in 2016,[11] 2021,[12] and 2022.[13]
References[edit]
- ↑ "David Ridley, PhD – Duke Health Sector Advisory Council". Retrieved 2024-05-28.
- ↑ "David Ridley". CEPR. 2017-11-02. Retrieved 2024-05-28.
- ↑ "David Ridley | Duke's Fuqua School of Business". www.fuqua.duke.edu. Retrieved 2024-05-28.
- ↑ Ridley, David B.; Grabowski, Henry G.; Moe, Jeffrey L. (2006-03-01). "Developing Drugs For Developing Countries". Health Affairs. 25 (2): 313–324. doi:10.1377/hlthaff.25.2.313. ISSN 0278-2715. PMID 16522573.
- ↑ John, Dingell (2007-09-27). "Cosponsors - H.R.3580 - 110th Congress (2007-2008): Food and Drug Administration Amendments Act of 2007". www.congress.gov.
- ↑ Finley, Allysia. "Medical Miracles From FDA Inefficiency". WSJ. Retrieved 2024-05-22.
- ↑ Ridley, David B.; Moe, Jeffrey L.; Hamon, Nick (2017-08-01). "A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases". Health Affairs. 36 (8): 1461–1468. doi:10.1377/hlthaff.2016.1640. ISSN 0278-2715. PMID 28784739.
- ↑ "Vector Expedited Review Voucher (VERV) Program". OCSPP. US EPA. 2023-12-20. Retrieved 2024-05-22.
- ↑ "HSM Faculty | HSM". centers.fuqua.duke.edu. Retrieved 2024-05-22.
- ↑ "History | HSM". centers.fuqua.duke.edu. Retrieved 2024-05-22.
- ↑ Schmitt, Jeff (2016-08-17). "Favorite Business School MBA Professors". Poets&Quants. Retrieved 2024-05-22.
- ↑ Schmitt, Jeff (2021-07-03). "2021 MBAs To Watch: Sarah Izzo, Duke University (Fuqua)". Poets&Quants. Retrieved 2024-05-22.
- ↑ Schmitt, Jeff (2022-09-06). "2022 MBA To Watch: Jordan Daniel Lantz, Duke University (Fuqua)". Poets&Quants. Retrieved 2024-05-22.
External links[edit]
This article "David Ridley (economist)" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:David Ridley (economist). Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
